Todays announcement is truly fabulous.These PC results illustrate Zantrenes potential to enhance AND compliment the anti-melanoma immune response.
PD-1 inhibitors created a paradigm shift in cancer immunotherapy.
When I think PD-1 inhibitors Keytruda (Merck) and Opdivo (Bristol Myers) spring to mind. If Zantrene synergises to overcome checkpoint inhibitor resistance and Keytruda success rate in patients is only ~ 15%. How many billions is Zantrene potentially worth to a company like Merck if their 15% success rate could be improved even by only 10-20% ?
Can't wait to watch how this all plays out the next 18 months !
Ann: Zantrene Improves Immune Therapy Treatment of Melanoma, page-39
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.55 |
Change
-0.070(4.32%) |
Mkt cap ! $264.0M | |||
| Open | High | Low | Value | Volume |
| $1.62 | $1.65 | $1.54 | $145.6K | 91.60K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5700 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 296 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |